- Home
- BCAX
BCAX
BICARA THERAPEUTICS INC
as 11-15-2024 4:00pm EST
Stocks
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.3B | IPO Year: | 2024 |
| Target Price: | $41.00 | AVG Volume (30 days): | 274.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -18.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.33 - $28.09 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BICARA THERAPEUTICS INC News
BCAX Breaking Stock News: Dive into BCAX Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Bicara Therapeutics' Q3 Loss Narrows
GlobeNewswire
5 days ago
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
6 days ago
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
TipRanks
a month ago
Opening Day: Another trio of biotech IPOs make Friday debut
Investing.com
a month ago
MBX Biosciences earns Buy rating at three investment firms
GuruFocus.com
2 months ago
RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares
GuruFocus.com
2 months ago
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc
GuruFocus.com
2 months ago
FMR LLC Acquires New Stake in Bicara Therapeutics Inc
Compare BCAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCAX BICARA THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.